Daily Endocrinology Research Analysis
Analyzed 89 papers and selected 3 impactful papers.
Summary
Three impactful endocrinology-related studies span mechanistic, translational, and precision-prevention advances. A Cell study reveals a skin–hypothalamus axis whereby heat stress primes the brain for later diet-induced metabolic dysfunction. Complementing this, a JCI study maps N-terminal apolipoprotein B interactions with endothelial receptors to curb atherogenic lipoprotein transport, while a JAMA Network Open analysis shows vitamin D’s diabetes-preventive effect depends on VDR ApaI genotype.
Research Themes
- Environmental heat stress imprinting central circuits and metabolic susceptibility
- Endothelial mechanisms of atherogenic lipoprotein transport and therapeutic targeting
- Pharmacogenetics guiding vitamin D supplementation for diabetes prevention
Selected Articles
1. A skin-hypothalamus axis couples heat stress and metabolic dysfunction.
In mice, prior heat exposure increased susceptibility to later diet-induced metabolic dysfunction. Mechanistically, heat stress elevated skin-derived KLK14 that imprinted hypothalamic signaling (involving LRRC7), revealing a peripheral–central axis that links environmental heat to durable metabolic vulnerability.
Impact: This work identifies a previously unrecognized skin–brain pathway that causally connects environmental heat stress to future metabolic disease risk, representing a potential paradigm shift in metabolic pathophysiology.
Clinical Implications: While preclinical, these findings suggest that cumulative heat exposure may be a modifiable risk factor for metabolic disease and nominate the KLK14–hypothalamic axis as a potential therapeutic target. Public health strategies mitigating heat exposure could have downstream metabolic benefits.
Key Findings
- Prior heat stress increased susceptibility to diet-induced metabolic dysfunction in mice.
- Heat stress elevated skin-derived KLK14, which imprinted hypothalamic signaling involving LRRC7.
- Defines a skin–hypothalamus axis linking environmental heat to durable metabolic vulnerability.
Methodological Strengths
- Integrative in vivo mechanistic approach linking peripheral signals to central circuits.
- Environmental exposure model coupled to molecular pathway characterization.
Limitations
- Preclinical mouse study; human generalizability remains to be established.
- Intervention reversibility, duration of imprinting, and precise cellular targets require further delineation.
Future Directions: Validate the KLK14–hypothalamus axis in humans, quantify heat exposure–metabolic risk relationships epidemiologically, and test pharmacologic or behavioral interventions that modulate this pathway.
With the ongoing rise in global temperatures, the prevalence of heat-stress-related chronic health disorders has increased. However, whether heat stress has an enduring impact on metabolic health remains unclear. Here, we report that mice exposed to heat stress were more susceptible to metabolic dysfunction upon subsequent exposure to an obesogenic diet. Upon heat stress, we found that elevated skin-derived kallikrein-related peptidase 14 (KLK14) imprinted hypothalamic LRRC7
2. The N-terminus of Apolipoprotein B mediates the interaction of atherogenic lipoproteins with endothelial cells.
Mapping the N-terminal APOB regions shows receptor-specific interactions: APOB48 uses SR-BI, while APOB100 engages ALK1 and SR-BI. The APOB18 fragment broadly reduces endothelial uptake and transcytosis of chylomicrons and LDL and, when overexpressed in mice, decreases atherosclerosis, highlighting a druggable APOB interface.
Impact: By pinpointing discrete APOB regions that drive endothelial lipoprotein handling and demonstrating in vivo atherosclerosis reduction, this work delivers a mechanistic foundation for novel anti-atherosclerotic strategies beyond LDL lowering.
Clinical Implications: Decoy peptides or small molecules mimicking APOB18, or strategies blocking ALK1/SR-BI–APOB interfaces, could complement lipid-lowering therapy by limiting endothelial lipoprotein entry and transcytosis.
Key Findings
- Distinct N-terminal APOB regions mediate binding to endothelial SR-BI and ALK1; APOB48 lipoproteins are internalized via SR-BI only.
- APOB18 (18% of N-terminus) reduces endothelial uptake and transport of both chylomicrons and LDL, whereas APOB12 selectively blocks ALK1-mediated uptake of APOB100 lipoproteins.
- Endothelial overexpression of APOB18 decreases atherosclerosis in hypercholesterolemic mice.
Methodological Strengths
- Convergent use of molecular modeling, mutagenesis, cell-based assays, and in vivo validation.
- Receptor-specific mapping enabling mechanistic dissection and therapeutic targeting.
Limitations
- Translatability and safety of APOB fragment-based interventions in humans remain untested.
- Focus on endothelial transport; systemic lipid metabolism and other vascular beds need evaluation.
Future Directions: Develop APOB18-mimetic therapeutics, evaluate pharmacokinetics and safety, and test efficacy in larger animal models and, ultimately, early-phase human trials.
Apolipoprotein B (APOB) containing lipoproteins contribute to atherosclerosis by entering the arterial wall through the endothelial cell (EC) surface receptors scavenger receptor-BI (SR-BI) and activin receptor-like kinase 1 (ALK1). We used N-terminal fragments of APOB, molecular modeling, and site-directed mutagenesis to identify and block the binding of chylomicrons and LDL to these receptors in cells and mice. We discovered that different APOB regions interact with SR-BI and ALK1 expressed on ECs APOB48 lipoproteins were only internalized by SR-BI. A fragment of APOB, comprising 18% of the N-terminal sequence, APOB18, reduced the uptake and transport of both chylomicrons and LDL by ECs, whereas a shorter fragment, APOB12, only blocked ALK1 mediated uptake of APOB100 containing lipoproteins. Importantly, overexpressing APOB18 decreased atherosclerosis in hypercholesterolemic mice. These findings identify the N-terminal region of APOB as the cause of atherosclerosis and illustrate an approach to treating or preventing vascular disease.
3. Vitamin D Receptor Polymorphisms and the Effect of Vitamin D Supplementation on Diabetes Risk Among Adults With Prediabetes.
In 2098 prediabetic adults from the D2d trial, vitamin D3 (4000 IU/d) lowered diabetes risk only in those with VDR ApaI AC/CC genotypes (HR 0.81), with no benefit in AA homozygotes (HR 1.02). These results support pharmacogenetic stratification to target vitamin D supplementation.
Impact: Demonstrates a gene-by-treatment interaction in diabetes prevention, offering a concrete path toward personalized vitamin D use rather than universal supplementation strategies.
Clinical Implications: Consider VDR ApaI genotyping when recommending high-dose vitamin D3 for diabetes risk reduction in prediabetes; benefits may be concentrated in AC/CC carriers, informing risk–benefit and cost-effectiveness.
Key Findings
- Among 2098 adults with prediabetes, vitamin D3 (4000 IU/d) reduced incident diabetes only in VDR ApaI AC/CC carriers (HR 0.81), with no benefit in AA homozygotes (HR 1.02).
- Discovery analysis linked intratrial 25(OH)D levels to diabetes risk in association with VDR polymorphisms.
- Models adjusted for site, race/ethnicity, sex, age, BMI, physical activity, statin use, and weight change; median follow-up 2.5 years.
Methodological Strengths
- Large, well-characterized RCT cohort with genotyping and intratrial 25(OH)D measurements.
- Two-stage (discovery/test) analytical approach with multivariable-adjusted hazard models.
Limitations
- Secondary genetic association analysis; external replication across ancestries is needed.
- Only three common VDR SNPs were assessed; broader genomic context and multiple-testing adjustments warrant consideration.
Future Directions: Prospective trials stratified by VDR genotype to confirm effect modification and evaluate cost-effectiveness of genotype-guided vitamin D supplementation.
IMPORTANCE: Achieving and maintaining a serum 25-hydroxyvitamin D (25[OH]D) level of 40 ng/mL or higher, compared with 20 to 30 ng/mL, may lower diabetes risk among adults with prediabetes. It is not known whether a genetically defined subgroup is more likely to experience benefits from targeting higher 25(OH)D levels with vitamin D3 supplementation. OBJECTIVE: To assess the role of common polymorphisms of the vitamin D receptor (VDR) in the association between supplementation with 4000 IU/d of vitamin D3 and the risk of diabetes among adults with prediabetes. DESIGN, SETTING, AND PARTICIPANTS: This genetic association study conducted a VDR genotype analysis of 3 common polymorphisms-ApaI, BsmI, and FokI-among 2098 participants in the Vitamin D and Type 2 Diabetes (D2d) clinical trial with available intratrial 25(OH)D levels and genotyping. The D2d trial was conducted from October 1, 2013, to November 28, 2018, with statistical analysis performed from January 3 to November 30, 2025. EXPOSURES: Receipt of 4000 IU/d of vitamin D3 vs placebo for a median of 2.5 years (IQR, 1.8-3.5 years). MAIN OUTCOMES AND MEASURES: In the discovery phase analysis among 1903 participants with available data, the risk of diabetes across different intratrial mean 25(OH)D levels in association with the VDR polymorphisms was examined. This was followed by a test phase analysis examining the response to vitamin D3 supplementation on incident diabetes among 2098 participants according to the ApaI genotypes. RESULTS: Of 2098 adults with prediabetes (mean [SD] age, 60.2 [9.9] years; 1169 men [55.7%]) in the test phase analysis, 618 with ApaI AA alleles exhibited no response to treatment with vitamin D3 (hazard ratio [HR], 1.02 [95% CI, 0.72-1.44]; models adjusted for study site, race and ethnicity, sex, baseline age, body mass index, usual physical activity, statin use, and intratrial weight change). In contrast, 1480 participants with ApaI AC and CC genotypes showed a 19% decrease in the risk of diabetes with vitamin D3 (HR, 0.81 [95% CI, 0.66-0.99]). CONCLUSIONS AND RELEVANCE: This genetic association study of adults with prediabetes suggests that diabetes risk reduction after supplementation with 4000 IU/d of vitamin D3 was restricted to participants carrying the AC and CC alleles of the ApaI polymorphism. These findings support the potential role of ApaI genotyping in identifying individuals most likely to experience benefits from high-dose vitamin D3 treatment to reduce diabetes risk.